2. Academic Validation
  3. Design, synthesis and biological evaluation of novel naphthoquinone derivatives as IDO1 inhibitors

Design, synthesis and biological evaluation of novel naphthoquinone derivatives as IDO1 inhibitors

  • Eur J Med Chem. 2018 Sep 5:157:423-436. doi: 10.1016/j.ejmech.2018.08.013.
Liangkun Pan 1,  Qiang Zheng 1,  Yu Chen 1,  Rui Yang 1,  Yanyan Yang 1,  Zhongjun Li 1,  Xiangbao Meng 2
Affiliations

Affiliations

  • 1 State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing, 100191, China.
  • 2 State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing, 100191, China. Electronic address: xbmeng@bjmu.edu.cn.
PMID: 30103191 DOI: 10.1016/j.ejmech.2018.08.013
Abstract

Indoleamine 2,3-dioxygenase 1 (IDO1) mediated kynurenine pathway of tryptophan degradation is identified as an appealing and novel target in immunotherapy for the treatment of Cancer. In this study, a novel series of naphthoquinone derivatives were synthesized, characterized and evaluated for their inhibitory activities against IDO1, and their structure-activity relationship was investigated. Among them, compounds T16, T44, T47, T49, T53 and T54 displayed potent IDO1 inhibitory activities with IC50 values ranging between 18 and 61 nM, which are more potent than INCB024360 undergoing clinical trial III evaluation. In addition, compounds T28, T44 and T53 decreased the kynurenine levels in rat plasma by 30%-50%. Compounds exhibiting excellent IDO1 inhibitory activities were also evaluated for their inhibitory activities against tryptophan 2,3-dioxygenase (TDO). Of which, compound T28 (IDO1 IC50 = 120 nM) showed promising TDO inhibition (IC50 72 nM) and was identified as an IDO1/TDO dual inhibitor.

Keywords

Cancer immunotherapy; Indoleamine 2,3-dioxygenase 1; Naphthoquinone derivatives; Tryptophan 2,3-dioxygenase.

Figures